CVS Caremark shares could reach $85 in a year, Barron's says CVS Caremark's move to stop selling tobacco products should bring in healthcare contract renewals, which more than make up for the EPS loss from tobacco sales. The stock could rise to $85 in a year, Barron's argues in a feature article. The company has a healthy dividend yield and buyback program, the paper adds. Reference Link
News For CVS From The Last 14 Days
Check below for free stories on CVS the last two weeks.